Pursuing vulnerable plaque biomarkers and druggable targets
This article was originally published in Start Up
Cambridge, UK-based PlaqueTec Ltd. is developing a coronary artery blood sampling technology combined with biomarker analysis to map the biological processes associated with the development and rupture of vulnerable plaque. The ambitious young company plans to use this information to detect and monitor plaque biomarkers, and then use these patented data to help identify drug candidates for atherosclerosis.
You may also be interested in...
Research takes deep dive into the implications around exempting certain orphan drugs that may qualify for the Inflation Reduction Act’s Medicare price negotiation program, including the effect of the exemption on Medicare spending and the revenue potential of those drugs.
In the latest venture capital and private equity funding deals in China, SanegeneBio, Argo Biopharma and Ausper Biopharma raised a combined $136m on the back of their early-stage small interfering RNA and antisense oligonucleotide assets.
PDC Brands declines to provide support for nine challenged claims for Dr. Teal’s line of balms, lotions, oils, soaps, sprays and other topicals. It continues using those after halting use of 25 other similar claims challenged by P&G, marketer of melatonin-containing ZzzQuil.